Ms. Wu Xia (吴夏) is a non-executive director of the Company, primarily responsible for overseeing the management and operations of the Group.

Ms. Wu has over 14 years of experience in research and private equity investment focusing on healthcare industry. Ms. Wu joined CICC Jia Cheng Investment Management Company Limited (中金佳成投资管理有限公司) in July 2008 and served as vice president from January 2012 to December 2014 and as executive director from January 2015 to August 2018. Ms. Wu transferred into CICC Capital Management Co., Ltd. (中金资本运营有限公司) (“CICC Capital”) in August 2018 as an executive director and has been serving as a managing director of CICC Capital since January 2019, where she is primarily responsible for the overall investment and management of CICC Kangrui I (Ningbo) Equity Investment Limited Partners (Limited Partnership) (中金康瑞壹期(宁波)股权投资基金合伙企业(有限合伙)). Ms. Wu has also been serving as a director of Genetron Holdings Limited, a company whose shares were previously listed on the NASDAQ under the trading symbol of “GTH” and delisted in March 2024, since September 2017, and a non-executive director of MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司), a medical device company whose shares are listed on the Stock Exchange (stock code: 2160). She was awarded “Outstanding Young PE Investor of the Year 2018” by China Renaissance (华兴资本) in 2018.

Ms. Wu obtained her bachelor’s degree in finance from Peking University (北京大学) in the PRC in July 2003 and her master’s degree in economics and finance from the University of Warwick in the United Kingdom in January 2005.